|
Male infertility
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
There was a significant relationship between male infertility and <i>CYP2D6 GG</i> genotype (<i>p</i> < 0.001).
|
31070506 |
2020 |
|
Dermatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In vivo relevancy of anti-inflammatory effects of CPD 6 was observed in acute and chronic skin inflammation models in mice.
|
31141897 |
2019 |
|
Nightmares
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Contrastingly, CYP2D6 SSRI substrates are associated with ADRs related to nightmares, withdrawal syndrome, and de-realization of cognitive processes.
|
31616600 |
2019 |
|
Rabies (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Cholesterol 25-hydroxylase suppresses rabies virus infection by inhibiting viral entry.
|
31552533 |
2019 |
|
Panic Attacks
|
0.010 |
Biomarker
|
disease |
BEFREE |
The top two ADRs associated with SSRIs metabolized by CYP2D6 are: nightmare (<i>n</i> = 983) reporting odds-ratio (OR) = 4.37 (95% confidence interval (CI) [3.67-5.20]) and panic attack (<i>n</i> = 1,243) OR = 2.43 (95% CI [2.11-2.79]).
|
31616600 |
2019 |
|
Acute intermittent porphyria
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
High penetrance of acute intermittent porphyria in a Spanish founder mutation population and CYP2D6 genotype as a susceptibility factor.
|
30808393 |
2019 |
|
Chronic small plaque psoriasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Patients with moderate to severe chronic plaque psoriasis (n = 21) received single oral doses of sensitive probe substrates for CYP1A2 (caffeine 100 mg), CYP2C9 (warfarin 10 mg), CYP2C19 (omeprazole 20 mg), CYP2D6 (metoprolol 50 mg), and CYP3A (midazolam 2 mg) on day 1, followed by 12 weeks of subcutaneous risankizumab treatment of 150 mg once every 4 weeks from day 8 to day 92, and again the same cocktail of substrates on day 98.
|
30574672 |
2019 |
|
Symptoms of stress
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
The predictors of delayed remission included unemployment (P = .004), severe medical comorbidity (P < .0001), severe baseline depression (P < .0001), more than 4 dysthymic symptoms (P = .005), more than 9 posttraumatic stress symptoms (P = .005), and serotonin receptor 1A (P = .006) and cytochrome P450 2D6 (P = .002 for C/T and P = .0004 for T/T) genetic variants.
|
29178685 |
2019 |
|
Functional Gastrointestinal Disorders
|
0.010 |
Biomarker
|
disease |
BEFREE |
Personalization is applied through pharmacogenomics related to drug pharmacokinetics, specifically the role of CYP2D6, 2C19 and 3A4 in the use of drugs for treatment of patients with FGIDs.
|
30886502 |
2019 |
|
Acute Chest Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This study aims to investigate the different clinically relevant allele variants (allele frequencies) of CYP2D6 gene and to determine whether a specific genotype of CYP2D6 gene (based on genetic polymorphism "allelic types" and combination) have impact on metoprolol effectiveness (clinical outcome) in patients who have acute coronary syndrome (ACS).
|
30965129 |
2019 |
|
Acute Coronary Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Correlation of CYP2D6 allelic polymorphism to outcome of acute coronary syndrome in mid-Euphrates Iraqi patients on metoprolol therapy.
|
30965129 |
2019 |
|
Acute dystonia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We theorize that CYP2D6 governs the risk of metoclopramide-related acute dystonia through its role in the synthesis of serotonin, which inhibits the dopamine tone.
|
31507424 |
2019 |
|
NONAKA MYOPATHY
|
0.010 |
Biomarker
|
disease |
BEFREE |
The finding of 5,6-ortho-quinone, the stable surrogate for the unstable 5-hydroxyprimaquine metabolite, almost exclusively in personnel with the NM phenotype, compared with sporadic or no production in those with the IM or PM phenotypes, provides further evidence for the role of CYP2D6 in radical cure.
|
31549155 |
2019 |
|
Inflammatory dermatosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In vivo relevancy of anti-inflammatory effects of CPD 6 was observed in acute and chronic skin inflammation models in mice.
|
31141897 |
2019 |
|
Nightmare Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
The top two ADRs associated with SSRIs metabolized by CYP2D6 are: nightmare (<i>n</i> = 983) reporting odds-ratio (OR) = 4.37 (95% confidence interval (CI) [3.67-5.20]) and panic attack (<i>n</i> = 1,243) OR = 2.43 (95% CI [2.11-2.79]).
|
31616600 |
2019 |
|
Ulcerative Colitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The current study suggests that CYP2D6*4 and MDR1 3435 C/T gene polymorphisms may be risk factors for UC susceptibility.
|
30551694 |
2018 |
|
Coronary heart disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CYP2D6 (C2850T, G1846A, C100T) polymorphisms, haplotypes and MDR analysis in predicting coronary artery disease risk in north-west Indian population: A case-control study.
|
29660517 |
2018 |
|
Dermatitis, Atopic
|
0.010 |
Biomarker
|
disease |
BEFREE |
The pharmacokinetics of five CYP450 substrates given orally (midazolam, omeprazole, S-warfarin, caffeine, and metoprolol, metabolized by CYP3A, CYP2C19, CYP2C9, CYP1A2, and CYP2D6, respectively) were evaluated before and 28 days after initiation of dupilumab treatment (subcutaneous 300 mg weekly) in 14 patients with moderate-to-severe atopic dermatitis.
|
29498038 |
2018 |
|
Eclampsia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset severe pre-eclampsia and response to labetalol therapy.
|
29789925 |
2018 |
|
Eczema
|
0.010 |
Biomarker
|
disease |
BEFREE |
The pharmacokinetics of five CYP450 substrates given orally (midazolam, omeprazole, S-warfarin, caffeine, and metoprolol, metabolized by CYP3A, CYP2C19, CYP2C9, CYP1A2, and CYP2D6, respectively) were evaluated before and 28 days after initiation of dupilumab treatment (subcutaneous 300 mg weekly) in 14 patients with moderate-to-severe atopic dermatitis.
|
29498038 |
2018 |
|
HIV Infections
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Likewise, CYP2D6*4 1934AA genotype was predominant in advanced HIV disease stage as compared to healthy controls (3.8% vs 0.6%, OR = 6.15).
|
30357957 |
2018 |
|
Leukopenia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CYP2D6 rs1135840 and NUDT15 rs116855232 increased the risks of hepatotoxicity and leukopenia with an odds ratio of 2.52 and 4.97, respectively.
|
29071720 |
2018 |
|
Obesity
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
EMA effectively resolves particularly challenging alignments in genomic regions that contain nearby homologous elements, uncovering variants in the pharmacogenomically important CYP2D region, and clinically important genes C4 (schizophrenia) and AMY1A (obesity), which go undetected by existing methods.
|
30138581 |
2018 |
|
Degenerative polyarthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, network analysis identified caspase-3 (CASP3), caspase-7 (CASP7), and cytochrome P450 2D6 (CYP2D6) as potential target genes; in addition, the TNF (Tumor necrosis factor) signaling pathway was linked to OA therapeutic action.
|
29891807 |
2018 |
|
Reoviridae Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
25-Hydroxycholesterol Production by the Cholesterol-25-Hydroxylase Interferon-Stimulated Gene Restricts Mammalian Reovirus Infection.
|
29950420 |
2018 |